Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature

SARS‐CoV‐2 infection can cause severe pneumonia (COVID‐19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS‐CoV‐2...

Descripción completa

Detalles Bibliográficos
Autores principales: Tepasse, Phil‐Robin, Hafezi, Wali, Lutz, Mathias, Kühn, Joachim, Wilms, Christian, Wiewrodt, Rainer, Sackarnd, Jan, Keller, Martin, Schmidt, Hartmut H., Vollenberg, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
COVID‐19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300950/
https://www.ncbi.nlm.nih.gov/pubmed/32557623
http://dx.doi.org/10.1111/bjh.16896
_version_ 1783547608614043648
author Tepasse, Phil‐Robin
Hafezi, Wali
Lutz, Mathias
Kühn, Joachim
Wilms, Christian
Wiewrodt, Rainer
Sackarnd, Jan
Keller, Martin
Schmidt, Hartmut H.
Vollenberg, Richard
author_facet Tepasse, Phil‐Robin
Hafezi, Wali
Lutz, Mathias
Kühn, Joachim
Wilms, Christian
Wiewrodt, Rainer
Sackarnd, Jan
Keller, Martin
Schmidt, Hartmut H.
Vollenberg, Richard
author_sort Tepasse, Phil‐Robin
collection PubMed
description SARS‐CoV‐2 infection can cause severe pneumonia (COVID‐19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS‐CoV‐2 viraemia with fatal outcome in patients after rituximab therapy.
format Online
Article
Text
id pubmed-7300950
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73009502020-06-18 Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature Tepasse, Phil‐Robin Hafezi, Wali Lutz, Mathias Kühn, Joachim Wilms, Christian Wiewrodt, Rainer Sackarnd, Jan Keller, Martin Schmidt, Hartmut H. Vollenberg, Richard Br J Haematol COVID‐19 SARS‐CoV‐2 infection can cause severe pneumonia (COVID‐19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS‐CoV‐2 viraemia with fatal outcome in patients after rituximab therapy. John Wiley and Sons Inc. 2020-06-22 2020-07 /pmc/articles/PMC7300950/ /pubmed/32557623 http://dx.doi.org/10.1111/bjh.16896 Text en © 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle COVID‐19
Tepasse, Phil‐Robin
Hafezi, Wali
Lutz, Mathias
Kühn, Joachim
Wilms, Christian
Wiewrodt, Rainer
Sackarnd, Jan
Keller, Martin
Schmidt, Hartmut H.
Vollenberg, Richard
Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
title Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
title_full Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
title_fullStr Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
title_full_unstemmed Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
title_short Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
title_sort persisting sars‐cov‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
topic COVID‐19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300950/
https://www.ncbi.nlm.nih.gov/pubmed/32557623
http://dx.doi.org/10.1111/bjh.16896
work_keys_str_mv AT tepassephilrobin persistingsarscov2viraemiaafterrituximabtherapytwocaseswithfataloutcomeandareviewoftheliterature
AT hafeziwali persistingsarscov2viraemiaafterrituximabtherapytwocaseswithfataloutcomeandareviewoftheliterature
AT lutzmathias persistingsarscov2viraemiaafterrituximabtherapytwocaseswithfataloutcomeandareviewoftheliterature
AT kuhnjoachim persistingsarscov2viraemiaafterrituximabtherapytwocaseswithfataloutcomeandareviewoftheliterature
AT wilmschristian persistingsarscov2viraemiaafterrituximabtherapytwocaseswithfataloutcomeandareviewoftheliterature
AT wiewrodtrainer persistingsarscov2viraemiaafterrituximabtherapytwocaseswithfataloutcomeandareviewoftheliterature
AT sackarndjan persistingsarscov2viraemiaafterrituximabtherapytwocaseswithfataloutcomeandareviewoftheliterature
AT kellermartin persistingsarscov2viraemiaafterrituximabtherapytwocaseswithfataloutcomeandareviewoftheliterature
AT schmidthartmuth persistingsarscov2viraemiaafterrituximabtherapytwocaseswithfataloutcomeandareviewoftheliterature
AT vollenbergrichard persistingsarscov2viraemiaafterrituximabtherapytwocaseswithfataloutcomeandareviewoftheliterature

Ejemplares similares